Integer Holdings Corporation (NYSE:ITGR) Given Consensus Recommendation of “Hold” by Analysts

Integer Holdings Corporation (NYSE:ITGR) has been assigned a consensus recommendation of “Hold” from the eleven analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $98.7143.

A number of research firms recently commented on ITGR. Piper Sandler reiterated an “overweight” rating and set a $97.00 price objective (up from $87.00) on shares of Integer in a research report on Friday, May 1st. Zacks Research cut Integer from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Weiss Ratings restated a “hold (c)” rating on shares of Integer in a research note on Thursday, June 18th. Finally, Citigroup upped their price target on shares of Integer from $89.00 to $92.00 and gave the company a “neutral” rating in a research report on Thursday, May 28th.

Integer Trading Up 0.0%

NYSE:ITGR opened at $95.18 on Tuesday. The company has a market cap of $3.23 billion, a PE ratio of 23.74, a price-to-earnings-growth ratio of 2.27 and a beta of 0.64. The company has a current ratio of 3.75, a quick ratio of 2.38 and a debt-to-equity ratio of 0.77. The company has a 50 day simple moving average of $89.92 and a two-hundred day simple moving average of $86.31. Integer has a 12 month low of $62.00 and a 12 month high of $122.99.

Integer (NYSE:ITGR) last released its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.21 by ($0.01). The firm had revenue of $439.58 million for the quarter, compared to the consensus estimate of $426.48 million. Integer had a net margin of 7.64% and a return on equity of 12.83%. Integer’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.31 earnings per share. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. Research analysts forecast that Integer will post 6.04 earnings per share for the current year.

Institutional Trading of Integer

Several large investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC raised its position in Integer by 48.1% in the first quarter. EverSource Wealth Advisors LLC now owns 360 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 117 shares during the period. Salomon & Ludwin LLC boosted its stake in shares of Integer by 46.8% during the 4th quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 118 shares during the last quarter. TD Private Client Wealth LLC grew its position in shares of Integer by 1,037.5% during the 4th quarter. TD Private Client Wealth LLC now owns 455 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 415 shares during the period. Parkside Financial Bank & Trust grew its position in shares of Integer by 135.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 464 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 267 shares during the period. Finally, Arax Advisory Partners increased its stake in shares of Integer by 2,489.5% in the 4th quarter. Arax Advisory Partners now owns 492 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 473 shares in the last quarter. 99.29% of the stock is currently owned by institutional investors.

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.